Sat, Oct 25, 2014, 12:18 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • ricardouno ricardouno Apr 11, 2013 8:04 AM Flag

    One Complete Response In Platinum Resistant Ovarian Cancer For DMUC5754A

    CancerNetwork, the internet home of the journal ONCOLOGY, reported on April 9 from the AACR that the Genentech phase I for its DMUC5754A ( using SGEN ADC technology ) showed one complete response in a patient with platinum resistant ovarian cancer.

    They note:

    "The phase I trial evaluated various doses of DMUC5754A in advanced ovarian and pancreatic cancer patients. DMUC5754A was administered at doses ranging from 0.3 mg/kg to 3.2 mg/kg every 3 weeks. Forty-four patients with advanced, recurrent, platinum-resistant ovarian cancer enrolled; of those, one complete response and four partial responses were reported. All patients who responded were treated with a 2.4 mg/kg dose of the drug and had high MUC16 expression in their tumor cells. Six additional patients had minor responses."

    Ricardo's opinion ( however, meaningless or of little value that might be ): Ricardo is impressed with a complete response in this setting. It seems to possibly ( my speculation only ) bode well for an eventual phase II at the 2.4 mg/kg dosing level with patients selected for higher MUC-16 cellular expression.

    Good luck to all !


    SortNewest  |  Oldest  |  Most Replied Expand all replies
35.95+0.35(+0.98%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.